425: Keen Vision Acquisition Corporation to Merge with Medera Inc., a Clinical-Stage Biotech Firm

Keen Vision Acquisition Corporation (KVAC) and Medera Inc. have entered into a definitive merger agreement, aiming to list Medera on NASDAQ with an implied initial enterprise value of approximately $622.6 million.

Summary

• Keen Vision Acquisition Corporation (KVAC) and Medera Inc., a clinical-stage biotechnology company, have announced a definitive merger agreement.
• The merger will result in Medera being listed on NASDAQ.
• The implied initial enterprise value of the combined company is approximately $622.6 million.
• Medera is focused on developing next-generation geneand cell-based approaches for treating cardiovascular diseases.
• Medera's founders and key shareholders have committed approximately $22.6 million via conversion of all shareholder loans.
• Existing Medera shareholders are rolling 100% of their equity into the combined company.
• Medera must have at least $40 million in available liquidity as a closing condition.
• The transaction is expected to close in the fourth quarter of 2024.
• Medera operates through two business units: Sardocor and Novoheart.
• Sardocor focuses on clinical development of novel therapies, while Novoheart provides human-based drug discovery and validation platforms.
• Sardocor has three ongoing AAV-based cardiac gene therapy clinical trials for Heart Failure with Reduced Ejection Fraction (HFrEF), Heart Failure with Preserved Ejection Fraction (HFpEF), and Duchenne Muscular Dystrophy-induced Cardiomyopathy (DMD-CM).
• SRD-001, for HFrEF, is in Phase 1/2a clinical trial (MUSIC-HFrEF; NCT0470384) with clinically meaningful improvements observed.
• SRD-002, for HFpEF, is in Phase 1/2a clinical trial (MUSIC-HFpEF; NCT06061549) with improvements in cardiovascular performance observed.
• SRD-003, for DMD-CM, is expected to dose the first patient in the fourth quarter of 2024 (MUSIC-DMD; NCT06224660).
• The merger values Medera at a pre-money valuation of $622.6 million.
• Cash proceeds from the transaction may reach approximately $149.50 million from KVAC's trust account, before any redemptions.
• The transaction includes a management incentive plan tied to the successful commercialization of the three clinical-stage assets.
• The boards of directors of both KVAC and Medera have unanimously approved the transaction.
• Approval by the shareholders of KVAC and Medera is required for the transaction to proceed.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the merger agreement, potential NASDAQ listing, and advancement of clinical programs. However, risks related to clinical trials, regulatory approvals, and potential need for additional capital temper the overall sentiment.

Positives

• Merger provides Medera with access to public markets and capital to advance its clinical programs.
• Medera's technology platform and clinical pipeline are validated by its collaboration and licensing arrangements with global pharmaceutical leaders.
• The merger includes a management incentive plan aligned with shareholder interests.
• Medera's approach of delivering gene therapy candidates directly to the heart via blood vessels minimizes side effects.
• The Novoheart platform accelerates drug development and regulatory approvals.
• The transaction has been unanimously approved by the boards of both companies.

Negatives

• The transaction is subject to shareholder approval and customary closing conditions, which could delay or prevent the merger.
• The cash proceeds from the transaction are dependent on the level of redemptions by KVAC's stockholders.
• Medera has a limited operating history and may never successfully commercialize its products.
• Medera expects to continue to incur significant losses and may never achieve or maintain profitability.
• The company is subject to risks related to clinical trials, regulatory approvals, and intellectual property protection.

Risks

• The transaction may not be completed in a timely manner or at all.
• Failure to satisfy the conditions to the consummation of the Transaction, including the adoption of the Merger Agreement by the shareholders of KVAC and the receipt of certain regulatory approvals.
• The inability to maintain the listing of KVACs securities or to meet listing requirements and maintain the listing of Mederas securities on Nasdaq.
• The risk that Medera will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all.
• Uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials.
• Risks related to regulatory review, and approval and commercial development.
• Risks associated with intellectual property protection.
• Medera expects to continue to incur significant losses and may never achieve or maintain profitability.
• The risk that additional financing in connection with the Transaction may not be raised on favorable terms.

Future Outlook

The combined company aims to advance Medera's clinical and preclinical programs, with a focus on expediting clinical trials for gene therapy candidates in HFrEF, HFpEF, and DMD-CM. Medera also plans to accelerate the application for an Investigational New Drug (IND) and the start of the Phase 1 trial for its next gene therapy candidate.

Management Comments

• Medera is uniquely positioned for sustainable growth with its one-of-a-kind technology platform and a broad portfolio of clinical and preclinical candidates, three of which are leading gene therapy candidates with ongoing FDA clinical trials.
• Achieving a Nasdaq listing will allow Medera to be better positioned for advancing our various clinical and preclinical programs, enabling more efficient development aimed at bringing novel therapeutic solutions to patients with unmet needs, stated Ronald Li, PhD, Chief Executive Officer and Founder of Medera.
• With this business combination, Sardocor will be well positioned to potentially expediate its three clinical trials for our lead gene therapy candidates in HFrEF, HFpEF and DMD-CM, said Roger Hajjar, MD, President, Chief Medical Officer and co-Founder of Medera.

Industry Context

This announcement reflects the ongoing trend of SPAC mergers in the biotechnology sector, where companies seek faster access to public markets to fund their research and development activities. Medera's focus on gene therapy aligns with the growing interest in this field for treating cardiovascular diseases.

Comparison to Industry Standards

• The $622.6 million implied enterprise value is within the typical range for clinical-stage biotech companies merging with SPACs, although valuations can vary widely based on the stage of development and potential market size of the therapies.
• Medera's three clinical-stage gene therapy programs are comparable to other companies in the gene therapy space, such as Sarepta Therapeutics and BioMarin Pharmaceutical, which are also developing gene therapies for genetic diseases.
• The use of a human mini-heart screening technology platform is a differentiating factor for Medera compared to companies relying solely on animal models for drug discovery.

Stakeholder Impact

• Shareholders of both KVAC and Medera will be impacted by the merger and the potential for future growth.
• Patients with cardiovascular diseases may benefit from the development of new therapies.
• Employees of Medera will be impacted by the changes associated with becoming a publicly traded company.

Next Steps

• KVAC and Medera will file a registration statement with the SEC, including a prospectus and proxy statement.
• KVAC will mail copies of the proxy statement to its shareholders to vote on the transaction.
• The transaction is subject to shareholder approval and customary closing conditions.
• Sardocor expects to complete the Phase 1/2a portion of the ongoing SRD-001 trial in the fourth quarter.
• Sardocor expects to dose the first patient in the SRD-003 trial in the fourth quarter.
• Sardocor expects to complete patient enrolment in both cohorts of the Phase 1/2a clinical trial for SRD-002 by the end of 2024.
• Sardocor expects to provide an interim data readout for the SRD-002 Phase 1/2a clinical trial in the first half of 2025.

Key Dates